Sight Sciences (SGHT)
NASDAQ:SGHT
Want to see SGHT full AI Analyst Report?
SGHT Stock Chart & Stats
$4.09
-$0.06(-1.81%)
At close: 4:00 PM EST
$4.09
-$0.06(-1.81%)
Day’s Range― - ―
52-Week Range$3.11 - $9.24
Previous CloseN/A
Volume59.09K
Average Volume (3M)150.61K
Market Cap
$260.62M
Enterprise Value$220.36M
Total Cash (Recent Filing)$84.96M
Total Debt (Recent Filing)$40.89M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding54,409,943
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.77
Enterprise Value/Gross Profit3.21
Enterprise Value/Ebitda-6.42
Forecast
1Y Price Target
$8.54Price Target Upside108.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$84.48M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently very high product-level gross margins (~83–86%) indicate durable unit economics for capital systems plus consumables. Strong margins support reinvestment in commercial expansion, improve leverage as volumes scale, and materially reduce the break-even revenue requirement over time.
Revenue Growth & Guidance RaiseReturn to double-digit YoY growth and a raised full-year revenue range signal improving demand and execution. Rebound across Interventional Glaucoma and emerging Dry Eye shows cross-sell potential and a multi-product growth profile that can sustain revenue momentum as payer access and commercial scale improve.
Improved Cash Discipline & RunwayMaterial cash balance plus sharply reduced quarterly cash burn provide a multi-quarter runway to execute commercial investments. Improved operating discipline and guidance to reach cash-flow breakeven without equity issuance lower financing risk and give management time to scale procedures and payer wins.
Bears Say
Persistent Losses & Cash DeficitDespite margin strength and recent revenue rebound, the company remains unprofitable with recurring negative operating and free cash flow. Continued losses erode equity and limit strategic flexibility, making sustained improvement in operating cash conversion critical to long-term viability.
Concentrated Dry Eye ReimbursementEarly TearCare traction relies on a small number of regional payer wins and limited active accounts. National commercial scale requires additional payer coverage and expanded sales capacity; until then Dry Eye revenue is fragile and dependent on localized reimbursement decisions.
Uncertain Legal Cash RecoveryA court award and ongoing royalty stream could materially strengthen the balance sheet, but proceeds are contingent on appeal outcomes and reexaminations. Timing and collectability are uncertain, so the judgment cannot be treated as a reliable source of near-term liquidity or funding for growth.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $3.11 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $260.62M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on May 06, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.066.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.15.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 54,409,943 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went up 23.023%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.54 (108.74% Upside)
$8.54 (108.74% Upside)
Hedge Fund Trend
Increased
By 29.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $308.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
-59.10%
Trailing 12-Months
Asset Growth
-15.41%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
SGHT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: the company returned to double‑digit revenue growth, raised 2026 revenue guidance, showed meaningful early traction in the newly reimbursed Interventional Dry Eye market, sustained very strong gross margins, and demonstrated improved cash usage and lower adjusted operating expenses. Challenges remain—most notably continued net losses, concentrated payer coverage for TearCare, early penetration of the dry eye opportunity, and uncertainty around timing of cash from the legal judgment—but these risks were framed as manageable and addressable with targeted commercial investment. On balance the positive progress, guidance raise, margin strength, and improving cash dynamics outweigh the outstanding risks.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$8.54
▲(108.74% Upside)
Technical Analysis
Ownership Overview
33.79% Insiders
5.89% Mutual Funds
13.91% Other Institutional Investors
39.39% Public Companies and
Individual Investors